P893 Budget impact analysis of introducing infliximab subcutaneous for the treatment of Inflammatory Bowel Disease in Latvia

Yoo, H.K.(1)*;Jang, M.Y.(1);Kwon, T.S.(2);

(1)Celltrion Healthcare, Global Market Access, Incheon, Korea- Republic Of;(2)Celltrion Healthcare, Global Marketing, Incheon, Korea- Republic Of;


Since the marketing authorisation of infliximab (IFX) subcutaneous (SC) in 2021, most of the western European countries had adopted CT-P13 SC. However, a few central and eastern European (CEE) countries including Latvia failed to adopt the new version of IFX. Infliximab SC injection at home significantly reduces number of outpatient visits and intravenous (IV) administrations. This is a tremendous benefit for countries with modest healthcare budget like Latvia because it will contribute to the effective use of hospital resources, especially in a pandemic era. This study describes the economic impact of introducing CT-P13 SC to the Latvian market from the perspective of society. 


A prevalence-based budget impact model was developed incorporating epidemiological data, administration cost data, and patient share data from Nacionālais Veselības Dienests (NVD). The analysis compared a "world with" CT-P13 SC scenario to a "world without" CT-P13 SC. The cost of IFX SC was assumed to be at parity to IFX IV which allows to capture the savings from the administration cost. This model compares annual cost of treatment including drug acquisition costs, administration cost and indirect cost of same molecule and further line of treatments (vedolizumab, ustekinumab, and tofacitinib).


This model estimates the financial impact on 2,000 patients with Crohn’s disease (CD) and ulcerative colitis (UC). Savings yield from IV administration cost is approximately €135,000 over the five-year period. Compared to the "world without" scenario, the introduction of CT-P13 SC resulted in cost savings of €1.03 million for treating CD and UC in Latvia over a 5-year period. The savings will be able to treat additional 220 patients, which equates to 11% of current patients, in a 5-year period.


Despite poor access to biologics in Latvia compared to other European countries, utilisation of IFX is high in Latvia compared to other biologics. Adding a SC treatment option to the existing care will not only improve patient outcome but also may lead to cost savings for the Latvian society. Parity pricing of IFX SC to IV IFX will enable budget reduction and result in improved patient experience with infliximab.